PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
22.47%
R&D growth less than half of RVPH's 30805.76%. David Dodd would verify if efficiency advantage is sustainable.
-1.59%
G&A reduction while RVPH shows 3.00% growth. Joel Greenblatt would examine efficiency advantage.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
14.64%
Operating expenses growth above 1.5x RVPH's 2.81%. Michael Burry would check for inefficiency.
14.64%
Total costs growth above 1.5x RVPH's 2.81%. Michael Burry would check for inefficiency.
No Data
No Data available this quarter, please select a different quarter.
8.11%
D&A growth while RVPH reduces D&A. John Neff would investigate differences.
-14.78%
EBITDA decline while RVPH shows 12.83% growth. Joel Greenblatt would examine position.
No Data
No Data available this quarter, please select a different quarter.
-14.64%
Both companies show declining income. Martin Whitman would check industry conditions.
No Data
No Data available this quarter, please select a different quarter.
-24.66%
Other expenses reduction while RVPH shows 457.55% growth. Joel Greenblatt would examine advantage.
-15.16%
Both companies show declining income. Martin Whitman would check industry conditions.
No Data
No Data available this quarter, please select a different quarter.
14.88%
Tax expense growth while RVPH reduces burden. John Neff would investigate differences.
-15.16%
Both companies show declining income. Martin Whitman would check industry conditions.
No Data
No Data available this quarter, please select a different quarter.
2.78%
EPS growth below 50% of RVPH's 29.17%. Michael Burry would check for structural issues.
2.78%
Diluted EPS growth below 50% of RVPH's 29.17%. Michael Burry would check for structural issues.
19.07%
Share count reduction exceeding 1.5x RVPH's 232.66%. David Dodd would verify capital allocation.
19.07%
Diluted share reduction exceeding 1.5x RVPH's 232.66%. David Dodd would verify capital allocation.